Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 3/20 | 0.34 |
| ▸ | MAX | P61244 | 3/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 3/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | PELP1 | Q8IZL8 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1343052 | 0.93 | MEN1 (0.35) | MYCMAXMKNK2GRM4EP300 | |
| SCHEMBL1342929 | 0.91 | MYC (0.36) | MYCMAXPTPN1EP300AR | |
| SCHEMBL1341479 | 0.90 | KMT2A (0.35) | MYCMAXMEN1KMT2AALDH1A1 | |
| SCHEMBL1342440 | 0.89 | MYC (0.35) | MYCMAXMKNK2GRM4PTPN1 | |
| SCHEMBL1343472 | 0.88 | GCK (0.36) | MYCMAXMKNK2GRM4PTPN1 | |
| SCHEMBL1343000 | 0.88 | GRM4 (0.39) | GRM4MEN1KMT2AMRGPRX1 | |
| SCHEMBL2650118 | 0.88 | GCK (0.33) | MKNK2GRM4 | |
| SCHEMBL1342447 | 0.84 | MEN1 (0.38) | MEN1KMT2AALDH1A1 | |
| SCHEMBL1342893 | 0.84 | MKNK2 (0.36) | MYCMAXMKNK2PTPN1 | |
| SCHEMBL1341764 | 0.83 | MAPT (0.37) | MYCMAXEP300MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-7897628-B2 | {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | MYC 180/4885MAX 2951/4885MKNK2 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.